Clinical trial
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
NCT02644369
Study timeline
Study start (actual)2016-03-21Date precision: day
Registry last updated2026-10-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Squamous Cell Cancer of Head and Neckunresolved
Triple Negative Breast Cancerunresolved
Epithelial Ovarian Cancerunresolved
Malignant Melanomaunresolved
Advanced Solid Tumorsunresolved
Interventions
PembrolizumabBIOLOGICAL
Sponsors & collaborators
University Health Network, Torontolead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02644369 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.